ERYTECH Provides Business and Financial Update for the Third Quarter of 20 2 2 Conference call and webcast on Tuesday, November 22, 2022 at 8:30am ET / 02:30pm CET Lead program Graspa halted F ocus on preclinical programs and partnering options Deep r estructuring implemented ; team size
ERYTECH Announces Receipt of N asdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 1 3 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today
Monthly information related to total number of voting rights and shares composing the share capital _ September 3 0 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C
ERYTECH Provides Business and Financial Update for the First Half of 20 2 2 Conference call and webcast on Tuesday, September 13, 2022 at 8:30am ET / 02:30pm CEST U.S. cell therapy manufacturing facility sold to Catalent in April 2022 Evaluation of partnering options ongoing, strategic
Monthly information related to total number of voting rights and shares composing the share capital _ Ju ly 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
Monthly information related to total number of voting rights and shares composing the share capital _ August 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH Provides Regulatory Update ERYTECH to stop further plans to pursue a BLA submission seeking an approval for Graspa ® in hypersensitive ALL Evaluation of strategic partnering options ongoing Cambridge, MA (U.S.) and Lyon (France) , August 2 4 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext:
Monthly information related to total number of voting rights and shares composing the share capital _ June 3 0 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
REPORT – ERYTECH ’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 2 4 , 20 22 Cambridge, MA (U.S.) and Lyon (France), June 24 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
Monthly information related to total number of voting rights and shares composing the share capital _May 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
